Florence Broussais

2.2k total citations · 1 hit paper
25 papers, 952 citations indexed

About

Florence Broussais is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Florence Broussais has authored 25 papers receiving a total of 952 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pathology and Forensic Medicine, 13 papers in Oncology and 8 papers in Immunology. Recurrent topics in Florence Broussais's work include Lymphoma Diagnosis and Treatment (13 papers), CAR-T cell therapy research (7 papers) and Immune Cell Function and Interaction (5 papers). Florence Broussais is often cited by papers focused on Lymphoma Diagnosis and Treatment (13 papers), CAR-T cell therapy research (7 papers) and Immune Cell Function and Interaction (5 papers). Florence Broussais collaborates with scholars based in France, Switzerland and Belgium. Florence Broussais's co-authors include Gilles Salles, Lionel Karlin, Franck Morschhauser, Catherine Thiéblemont, Emanuele Zucca, Sandy Amorim, David Cunningham, Mary Gleeson, Patrice Herait and Thierry Façon and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Florence Broussais

24 papers receiving 940 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

2016 328 citations Sandy Amorim, Anastasios Stathis et al. The Lancet Haematology profile →

Peers

Florence Broussais

ONCOL

IMMUN

PFM

HEMAT

Sophie Tartas France

Elisabetta Todisco Italy

Felicitas Hitz Switzerland

Sascha A. Tuchman United States

Khaled El‐Shami Israel

Andrew Belch United States

C. Michel Zwaan Netherlands

Clíona Grant United States

Thomas J. Semrad United States

Rosa Giuliani Italy

Sophie Tartas France

Florence Broussais

248 ×0.7

ONCOL

128 ×0.4

228 ×0.9

IMMUN

148 ×0.7

PFM

53 ×0.2

HEMAT

Citations per year, relative to Florence Broussais Florence Broussais (= 1×) peers Sophie Tartas

Countries citing papers authored by Florence Broussais

Since Specialization

Citations

This map shows the geographic impact of Florence Broussais's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florence Broussais with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florence Broussais more than expected).

Fields of papers citing papers by Florence Broussais

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florence Broussais. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florence Broussais. The network helps show where Florence Broussais may publish in the future.

Co-authorship network of co-authors of Florence Broussais

This figure shows the co-authorship network connecting the top 25 collaborators of Florence Broussais. A scholar is included among the top collaborators of Florence Broussais based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florence Broussais. Florence Broussais is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Combes, Jean‐Damien, et al.. (2022). Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France. EClinicalMedicine. 54. 101674–101674. 26 indexed citations

Broussais, Florence, et al.. (2021). Lettre type pour les comptes rendus « CAR-T Cells » : recommandations de la Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Bulletin du Cancer. 108(12). S82–S86.

Broussais, Florence, Jacques Olivier Bay, Nicolas Boissel, et al.. (2021). DESCAR-T, le registre national des patients traités par CAR-T Cells. Bulletin du Cancer. 108(10). S143–S154. 8 indexed citations

Vey, Norbert, Lionel Karlin, Florence Broussais, et al.. (2018). A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. Oncotarget. 9(25). 17675–17688. 110 indexed citations

Cottereau, Anne‐Ségolène, Tarec Christoffer El‐Galaly, Stéphanie Becker, et al.. (2017). Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients. Journal of Nuclear Medicine. 59(4). 589–595. 44 indexed citations

Thibult, Marie‐Laure, Sonia Pastor, Françoise Gondois‐Rey, et al.. (2016). Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy. Cancer Research. 76(16). 4648–4660. 58 indexed citations

Cottereau, Anne‐Ségolène, Stéphanie Becker, Florence Broussais, et al.. (2016). Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). Annals of Oncology. 27(4). 719–724. 75 indexed citations

Amorim, Sandy, Anastasios Stathis, Mary Gleeson, et al.. (2016). Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. The Lancet Haematology. 3(4). e196–e204. 328 indexed citations breakdown →

Mounier, Nicolas, S. Anthony, Catherine Thiéblemont, et al.. (2016). Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study.. Journal of Clinical Oncology. 34(15_suppl). 7518–7518. 1 indexed citations

10.

Coiffier, Bertrand, Catherine Thiéblemont, Sophie de Guibert, et al.. (2016). A phase II, single‐arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B‐cell lymphoma. British Journal of Haematology. 173(5). 722–730. 46 indexed citations

11.

Grados, A., Mikaël Ebbo, E. Bernit, et al.. (2015). Sarcoidosis Occurring After Solid Cancer. Medicine. 94(28). e928–e928. 36 indexed citations

12.

Nunès, Jacques A., Céline Castanier, Raynier Devillier, et al.. (2014). Constitutive AKT activation in follicular lymphoma. BMC Cancer. 14(1). 565–565. 17 indexed citations

13.

Castagna, Luca, Stéfania Bramanti, S. Fürst, et al.. (2014). Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. Bone Marrow Transplantation. 49(12). 1475–1480. 26 indexed citations

14.

Olive, Daniel, Mikaël Roussel, Florence Broussais, et al.. (2014). Diffuse Large B Cell Lymphoma (DLBCL) infiltrating T Cells Display an Activated and Exhausted Status and Are Inhibited By Ligands of Cosignaling Receptors Including PD-L1, PD-L2 and CD80 Expressed By Most DLBCL in Situ. Blood. 124(21). 1665–1665. 1 indexed citations

15.

Thiéblemont, Catherine, Anastasios Stathis, Giorgio Inghirami, et al.. (2014). A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies. Blood. 124(21). 4417–4417. 6 indexed citations

16.

Lazarovici, Julien, Pauline Brice, Lucie Obéric, et al.. (2014). Management and Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Retrospective Study By the Lymphoma Study Association. Blood. 124(21). 3054–3054. 2 indexed citations

17.

Crocchiolo, Roberto, Thomas Prébet, Florence Broussais, et al.. (2013). Impact of Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation on Women's Fertility. Clinical Lymphoma Myeloma & Leukemia. 13(6). 704–710. 22 indexed citations

18.

Ranchon, Florence, Gilles Salles, Hans-Martin Späth, et al.. (2011). Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer. 11(1). 478–478. 93 indexed citations

19.

Villar, Emmanuel, et al.. (2007). IgA-mediated autoimmune haemolytic anaemia in a 9-year renal transplanted patient. Clinical Kidney Journal. 1(1). 28–29. 2 indexed citations

20.

Broussais, Florence, Nicolas Mounier, Coralie Bélanger, et al.. (2005). Survival Impact of Time Repeated bcl2/IgH Rearrangement Measurements in Follicular Lymphoma Patients Treated with Front-Line Autotransplantation in the GELF-94 Trial by the GELA.. Blood. 106(11). 981–981. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact